GxPinnacle Logo
Skip to content

What Do Inspectors Check for Safety Data Exchange Timelines and Compliance?

Safety Data Exchange Agreements must define clear timelines for exchanging valid cases, follow-up information, and safety communications. Regulators expect day zero rules, case forwarding windows, acknowledgements, and compliance monitoring to be clearly documented and followed.

For: Founders, CEOs & MDs·PV Leads·QA/Compliance·Scientists tasked with documentation

Alignment: Global pharmacovigilance principles (ICH-aligned) and inspection practices

Most useful when: Preparing for inspection, setting up a process, or closing a documentation gap

Key points

  • Safety Data Exchange Agreements must define clear timelines for exchanging valid cases, follow-up information, and other safety data.
  • Day zero rules must be stated explicitly so that both parties calculate regulatory timelines consistently.
  • Timelines for initial case forwarding, follow-up exchange, acknowledgements, and urgent escalation must be operationally workable and aligned with regulatory requirements.
  • Compliance with agreed timelines must be monitored and documented.
  • Delays, discrepancies, or missed exchanges must trigger investigation and escalation.
  • Inspection-ready evidence should demonstrate that safety data exchange timelines are not only written in the agreement but actively monitored in practice.

What inspectors expect

Each point below should be supported by controlled documents and traceable records.

  • Safety data exchange timelines must be defined clearly and without ambiguity.
  • Day zero must be applied consistently across parties.
  • Case forwarding timelines must support downstream regulatory reporting obligations.
  • Compliance with agreed timelines must be monitored and documented.
  • Late or failed exchanges must be investigated and escalated.

Summary

Inspectors assess whether Safety Data Exchange Agreements define and enforce clear timelines for exchanging safety information. They typically review day zero handling, valid case forwarding windows, follow-up timing, acknowledgements, escalation rules, and evidence that compliance with the agreement is monitored and acted upon.

Common questions

These are the questions this page is designed to answer directly.

  • What timelines should be defined in a Safety Data Exchange Agreement?
  • How quickly must ICSRs be exchanged between partners?
  • How is day zero handled in an SDEA?
  • What do inspectors check for SDEA timelines and compliance?
  • How should follow-up timelines be managed in safety data exchange?
  • What happens if case exchange is delayed between parties?
  • How do you monitor compliance with SDEA timelines?
  • What timeline applies for forwarding valid ICSRs to a partner?
  • How do inspectors verify SDEA compliance?
  • What are common timeline failures in pharmacovigilance agreements?

Evidence objects inspectors expect

SDEA Timeline Clauses

  • Defined timeline for forwarding valid ICSRs between parties
  • Defined timeline for follow-up information exchange
  • Acknowledgement requirements for received cases
  • Urgent escalation timelines for critical safety issues
  • Business day versus calendar day definitions

Day Zero and Receipt Handling Rules

  • Agreed definition of day zero
  • Rules for determining first awareness of a valid case
  • Consistent marking of receipt date on shared cases
  • Documentation showing how day zero is communicated between parties

Compliance Monitoring Outputs

  • Tracking of case exchange timeliness
  • Metrics showing on-time versus late case forwarding
  • Exception logs for delayed transmissions
  • Periodic review of compliance against agreed timelines

Acknowledgement and Escalation Records

  • Evidence that receiving parties acknowledge case receipt
  • Escalation logs for delayed or missing safety data transfers
  • Communication trails for urgent case handling
  • Corrective actions triggered by timeline failures

Reconciliation and Late Case Investigation

  • Reconciliation outputs identifying missing or late cases
  • Investigation records for delayed exchange
  • Root cause analysis for timeline breaches
  • CAPA linked to repeated compliance failures

Regulatory Basis (Primary Sources)

  • GVP Module VI – requirements for timely collection, exchange, and reporting of ICSRs
  • GVP Module I – quality systems and compliance monitoring for pharmacovigilance activities
  • ICH E2D – post-approval safety data management and expedited reporting expectations
  • MHRA GPvP guidance – expectations for timely reporting and compliant pharmacovigilance processes
  • FDA postmarketing safety reporting guidance – obligations for timely safety reporting and regulatory compliance

Typical Inspection Questions (What Inspectors Ask)

  • What timeline applies for forwarding a valid case to your partner or vendor?
  • How do both parties define day zero?
  • How do you monitor compliance with SDEA timelines?
  • Show me evidence of any late case exchanges and how they were handled.
  • How do you ensure delayed partner forwarding does not lead to regulatory late reporting?

Failure patterns

The agreement contains vague or impractical exchange timelines.

Day zero is interpreted differently by the two parties.

Valid cases are forwarded too late to support compliant regulatory reporting.

Follow-up information is exchanged inconsistently or without traceable timing.

Timeline breaches occur repeatedly without escalation, investigation, or CAPA.

What good looks like

  • Clear, practical, and enforceable timelines written into the agreement.
  • Consistent day zero handling across all parties.
  • On-time forwarding of valid cases and follow-up information.
  • Active monitoring of timeliness with late cases investigated promptly.
  • Escalation and CAPA processes triggered where compliance risks arise.

Operationalisation

  • Define case exchange timelines in calendar days or business days with no ambiguity.
  • Document a shared day zero rule and train both parties to apply it consistently.
  • Implement tracking for valid case forwarding, follow-up exchange, and acknowledgements.
  • Review exchange timeliness through regular governance and reconciliation activity.
  • Escalate delayed or missing transmissions immediately where regulatory risk exists.
  • Trend timeline breaches and implement CAPA where repeated failures occur.

Need regulatory documentation today?

Save time and reduce inspection risk with structured, pre-built process-ready documentation.
Created by industry professionals, adaptable to your organisation.

Related pre-built documentation inside the app

Get AccessLog In

FAQ

What timelines should be included in a Safety Data Exchange Agreement?

An SDEA should define timelines for forwarding valid ICSRs, exchanging follow-up information, acknowledging receipt, escalating urgent safety issues, and resolving reconciliation discrepancies.

How is day zero handled in a Safety Data Exchange Agreement?

The agreement should define day zero explicitly as the date a valid case is first received, and both parties should apply that rule consistently so regulatory timelines are calculated correctly.

Why are data exchange timelines important in pharmacovigilance?

Data exchange timelines are important because delays between parties can cause late regulatory reporting, compliance breaches, and inspection findings.

Do inspectors review SDEA timeline compliance?

Yes. Inspectors frequently review whether agreed timelines are realistic, whether they are followed in practice, and how late exchanges are investigated and escalated.

What are common timeline failures in SDEAs?

Common failures include unclear day zero definitions, late forwarding of valid cases, delayed follow-up exchange, missing acknowledgements, and lack of investigation into repeated delays.

How quickly must adverse events be shared between partners in pharmacovigilance?

Timelines are defined in the Safety Data Exchange Agreement, but valid ICSRs are typically shared within a few calendar days of receipt to ensure regulatory reporting timelines can still be met.

How do companies monitor compliance with SDEA timelines?

Companies typically monitor compliance through timeliness tracking, reconciliation outputs, governance reviews, exception logs, and CAPA where breaches occur.

Sources

Primary guidance used to inform this map. This page is a structured interpretation layer; always validate against the original source documents.

European Medicines Agency (EMA)

  • Guideline on good pharmacovigilance practices (GVP) – Module I
    View source
  • Guideline on good pharmacovigilance practices (GVP) – Module VI
    View source

International Council for Harmonisation (ICH)

  • Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting (E2D)
    View source

U.S. Food and Drug Administration (FDA)

  • Postmarketing Safety Reporting for Human Drug and Biological Products
    View source

UK MHRA